ArticleVirchows Archiv : an international journal of pathology2026
A rare solid tumor frequently misdiagnosed as lymphoma: primary colonic Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPrimary colonic Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma (EBV+ iFDCS) is a rare, poorly characterized neoplasm. This study aims to delineate its clinicopathological features and thereby facilitate accurate diagnosis.
methodsThis study retrospectively analyzed 14 cases of primary colonic EBV+iFDCS and conducted a systematic review of 18 additional cases from the literature.
resultsThe median age was 51 years (range, 35-68 years), with 10 females and 4 males. All cases were confined to the colon, with the transverse colon as the most common site (50%, 7/14), followed by the descending colon (28.6%, 4/14), sigmoid colon (14.3%, 2/14), and ascending colon (7.1%, 1/14). The vast majority of cases (85.7%, 12/14) were asymptomatic and were incidentally detected during routine physical examinations. Endoscopically, the tumors presented as either pedunculated polyps (9 cases) or sessile polypoid lesions (5 cases) with surface congestion. Their histology was characterized by mucosal erosion, prominent superficial perpendicular vessels, and secondary lymphoid follicular (SLF)hyperplasia. Neoplastic spindle cells were arranged in scattered and fascicular patterns within a background of plasma cells and small lymphocytes. Morphological subtypes comprised classic/lymphoma-like mixed type (64.3%, 9/14) and lymphoma-like type (35.7%, 5/14). Tumor cells expressed multiple FDC markers (CD21, CD23, CD35), co-expressed SMA (100%, 13/13) and CD56 (100%, 12/12), while SSTR2 was typically negative or only weakly expressed. The microenvironment was characterized by a B-cell predominance. EBV-encoded RNA was detected in perivascular and interfollicular tumor cells, with positivity also in germinal center FDCs. Clonality assays were negative in all but two cases (one case each with TCR rearrangement and IG rearrangement). All patients were underwent endoscopic submucosal resection, with no recurrence or major complications.
conclusionPrimary colonic EBV+iFDCS is a distinct, low-grade malignant neoplasm that typically presents as polyp or polypoid lesion. Its hallmark histologic features include a characteristic arrangement of vessels and SLFs in a prominent lymphocytic background. The tumor exhibits a dual immunophenotype, expressing markers of both FDCs and follicular reticular cells. Because the disease follows an indolent clinical course with a favorable prognosis, accurate diagnosis is essential to avoid overtreatment.
Indexed as
Identifiers
42207301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.